Daiichi Sankyo, Inc. is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for hypertension, pain management, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma.
Daiichi Sankyo
Unlock to Claim this listing
Add / Modify Company
Click to rate this company
[Total: 0 Average: 0]
Click here to sign in to vote
3.25
Overall Excellence Rating
Industry
Pharmaceuticals & BiotechnologyCategory
Pharmaceutical ManufacturingESG/Ethical Impact
The Daiichi Sankyo Group is addressing sustainability issues through its business based on the Daiichi Sankyo Group Corporate Conduct Charter. The Daiichi Sankyo Group Corporate Conduct Charter defines principles to be practiced in all of the Company’s activities in order to fulfill its corporate mission. Taking each of these principles seriously and complying with laws, regulations and rules, we act with the highest ethical standards and good social conscience appropriate for a company engaged in a business that affects human lives. Through this commitment, we strive to meet the diverse requirements and expectations of society to enhance our corporate value and thereby fulfill our social responsibility and contribute to the realization of a sustainable society.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.
Awards Received
2023
Revenues
10200000000
Website Traffic
Employee Rating
3.9
Customer Rating
3.5
Company Size
10000+
ESG Risk Rating
4
We’re Happy to Help.
Do you have questions about your ranking, our projects, or why you’re not on the list?